Selvita, an integrated service provider supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development, agreed to acquire Fidelta, a contract research organization, from Galapagos,a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines, for $38m. “With this acquisition, we are not only executing our strategy announced this year, but we’re actually taking a leap in both the scope of our services portfolio and the scale of business. It is a transformative moment in the history of Selvita," Boguslaw Sieczkowski, Selvita CEO.